Researchers analyzed 203 patients meeting the criteria for high risk, with a history of positive C. diff polymerase chain reaction test and symptoms of C. diff. The patients were divided into two groups — 71 in the vancomycin prophylaxis group and 132 in the group that did not receive vancomycin prophylaxis.
The study found that one patient in the vancomycin prophylaxis group developed C. diff while 35 patients developed C. diff in the group that did not receive vancomycin prophylaxis.
A prospective study could potentially stratify patients at risk for recurrent C. diff and determine which populations may benefit most from secondary prophylaxis with oral vancomycin, noted the poster authors.
More articles on quality:
New, inexpensive lab test identifies CRE in hours
What insect’s bacteria could replace antibiotics?
Rare respiratory virus sweeping through US: What healthcare providers need to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
